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Abstract
Background: Accumulating evidence suggests that high-density lipoprotein (HDL) cholesterol is associated with
pulmonary function and pulmonary disorders. The aim of this study was to evaluate the association between HDL
cholesterol and pulmonary function in healthy adolescents.
Methods: This cross-sectional study was based on data collected for the JS High School study. The analysis included
644 adolescents (318 male and 326 female) aged 15–16 years old and free from asthma or chronic obstructive pulmonary
disease. Fasting blood samples were collected for hematologic and biochemical assessment. Forced vital capacity volume
(FVC) and forced expiratory volume in the 1 s (FEV1) were measured using dry-rolling-seal spirometry. The associations
between HDL cholesterol and pulmonary function were analyzed using multiple linear regression models.
Results: Among male adolescents, an increase of 1.0 mg/dL in HDL cholesterol was associated with 10 mL decrease in
FVC (p = 0.013) and FEV1 (p = 0.013) after adjusting for age, height, weight, alcohol drinking, smoking, physical activity,
systolic blood pressure, total cholesterol, triglyceride, and monthly household income. Percent predicted values of FVC
(p = 0.036) and FEV1 (p= 0.017) were also inversely associated with HDL cholesterol. However, among female adolescents,
HDL cholesterol level was not significantly associated with absolute or percent predictive value of FVC and FEV1.
Conclusions: Higher HDL cholesterol level may be associated with decreased pulmonary function among healthy male
adolescents. The sex differences observed in the association between HDL cholesterol and pulmonary function need
further investigation.
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Background
High-density lipoprotein (HDL) is one of the five major
groups of lipoproteins. HDL is found associated with apo-
lipoprotein M more than other lipoproteins for the reason
that apolipoprotein M is important for the formation of
pre-beta HDL and for reverse cholesterol transport [1, 2].
HDL cholesterol is known to reduce macrophage accumu-
lation [3] and to transport fat molecules out of artery walls
[4], thereby preventing atherosclerosis [5, 6] and cardio-
vascular disease [7, 8]. For this reason, HDL cholesterol as
a therapeutic target for atherosclerotic disease seems
attractive strategy towards preventing cardiovascular dis-
ease. However, recent clinical trials aimed at increasing
HDL cholesterol levels failed to observe any prevention of
cardiovascular disease [9, 10]. Similarly, in a Mendelian
randomization study, genetically increased HDL cholesterol
levels did not reduce the risk of myocardial infarction [11].
Recent studies suggest that HDL cholesterol and apolipo-
protein M may be associated with pulmonary function [12,
13]. A pooled analysis of seven cohort studies indicated that
higher HDL cholesterol levels were independently associated
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with poorer pulmonary function [12]. Higher HDL choles-
terol level was also positively associated with per cent
emphysema measured by CT scan in the Multi-Ethnic Study
of Atherosclerosis [12]. Apolipoprotein M was elevated in
patients with chronic obstructive pulmonary disease and the
level increased gradually as disease severity increased [13].
These finding imply that HDL cholesterol plays a significant
role in pulmonary function. However, to date no research
has been conducted on the relationship between HDL chol-
esterol and pulmonary function in healthy adolescents.
Therefore, in this study, we investigated the possible associ-
ation between HDL cholesterol level and pulmonary func-
tion in healthy adolescents.
Methods
Study population
Our study was based on data collected for the JS High
School study, a prospective cohort study of a Korean ado-
lescent population [14]. The target population of the JS
High School study was first-graders at a high school
located in a rural area of South Korea. Baseline examina-
tions were conducted on 1071 participants in years 2007,
2010, 2011, and 2012. Pulmonary function tests were con-
ducted in years 2007, 2010, and 2011 and the reproduci-
bility of the results was confirmed by a respiratory
physician. Among the 830 participants who underwent
pulmonary function testing, we selected 644 (318 male
and 326 female) participants after excluding 170 partici-
pants who had poorly reproducible results and 16 partici-
pants who were diagnosed with and treated for asthma
and respiratory diseases. Informed consent was obtained
from each student as well as from his/her parent or guard-
ian after full explanation of the purpose and process of the
study. The study protocol and consent procedure were
approved by the Institutional Review Board of Severance
Hospital at Yonsei University College of Medicine.
Measurements
Health-related lifestyle factors and personal and family
disease history were evaluated using self-administered
questionnaires (Additional file 1). Smokers were defined
as participants who smoked more than 100 cigarettes in
their lifetime. Drinkers were defined as participants who
consumed alcoholic beverages at least once a month over
the last year. Regular exercise was defined as engaging in
physical activity on a regular basis, for at least 30 min
once a week at moderate intensity, either indoor or out-
door. Monthly household income was classed into three
groups: low (<3,000,000 Korean won per month), middle
(3,000,000 to 5,000,000 Korean won per month), and high
(>5,000,000 Korean won per month). Anthropometric
measurements were performed according to a predefined
protocol. Height was measured to the nearest 0.1 cm using
a stadiometer. Body weight was measured to the nearest
0.1 kg on a digital scale, with the subject wearing his/her
school uniform. Body mass index was calculated as weight
in kilograms divided by the square of height in meters (kg/
m2). Waist circumference was measured between the lower
borders of the rib cage and the iliac crest with a measuring
tape. Resting blood pressure was measured twice, at 5-min
intervals, using an automatic sphygmomanometer (Dina-
map 1846 SX/P, USA) with the participant in the sitting
position. If the two readings differed by more than
10 mmHg, additional readings were obtained and the last
two readings were averaged. Fasting blood samples were
drawn after at least an 8-h fast. Serum concentrations of
total cholesterol, HDL cholesterol, and triglycerides were
measured by enzymatic methods using an autoanalyzer
(ADVIA 1800, Siemens Healthcare Diagnostics Inc., Deer-
field, IL, USA).
Pulmonary function testing was conducted using a vol-
ume displacement spirometer (model 1022; Sensor Medics;
Yorba Linda, USA) after instruction and a practice attempt,
in the seated position with nose clips applied. Participants
performed at least three different forced expiration maneu-
vers to provide estimates of forced vital capacity (FVC) and
forced expired volume in 1 s (FEV1), according to the
guidelines of the American Thoracic Society and European
Respiratory Society [15]. If the spirometry was judged as
not being optimal or showing obstruction, the participants
were asked to perform up to eight times. The best forced
expiratory volume was recorded from each set of measure-
ments. The percent predicted values of FVC (%FVC) and
FEV1 (%FEV1) were calculated according to Polgar’s for-
mula, correcting sex, age, height, and weight [16].
Statistical analysis
Data are presented either as mean with standard deviation
or number with percent. Differences between male and
female participants were analyzed using either the inde-
pendent t-test or χ2-test. Correlations between variables
were evaluated using Spearman’s correlation coefficient.
Multiple linear regression models were used to examine
the association between HDL cholesterol level and
pulmonary function, adjusting for potential confounding
variables including age, height, weight, physical activity
level, systolic blood pressure, and total cholesterol and tri-
glyceride levels. All statistical analyses were performed
using SAS version 9.2 (SAS Institute, Cary, NC, USA).
Statistical significance was defined as a two-sided p-value
less than 0.05.
Results
The clinical and biochemical characteristics of participants
are presented in Table 1. Pulmonary function indices such
as FVC, %FVC, FEV1, and %FEV1 were higher in male par-
ticipants. Total cholesterol, HDL cholesterol, and low-
density lipoprotein (LDL) cholesterol were higher in female
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participants. The proportions of current smokers and
drinkers were significantly higher among male participants,
who also engaged more regularly in exercise than their
female counterparts. No participants had been diagnosed
with diabetes mellitus or hypertension.
Table 2 shows the correlations between HDL choles-
terol level and pulmonary function indices, including
FVC, FEV1, and FEV1/FVC ratio. HDL cholesterol showed
significant negative correlations with values of FVC (r=
−0.158, p= 0.005), FEV1 (r=−0.137, p= 0.015), %FVC (r=
−0.172, p= 0.002), and %FEV1 (r=−0.165, p= 0.003) in
male adolescents. However, in female adolescents, HDL
cholesterol showed significant negative correlations with
only %FVC (r=−0.112, p= 0.044). In both sexes, FEV1/FVC
ratio was not correlated with HDL cholesterol level. Pul-
monary function was positively correlated with BMI and
systolic blood pressure in both male and female adoles-
cents, but was only positively correlated with age in male
participants. Figures 1 and 2 show the sex differences in the
linear relationship between HDL cholesterol and %FVC
and %FEV1, respectively. HDL cholesterol was significantly
and inversely associated with %FVC and %FEV1 in male
adolescents only. The scatterplots show a considerable sex
difference in the association between HDL cholesterol and
pulmonary function.
The results of the multiple linear regression analyses
of HDL cholesterol and pulmonary function are shown
in Table 3. Among male adolescents, the level of HDL
cholesterol showed significant negative associations with
FVC (β = −0.010, p = 0.028), FEV1 (β = −0.010, p =
0.014), %FVC (β = −0.192, p = 0.036), and %FEV1 (β =
−0.210, p = 0.017), even after adjusting for age, height,
weight, smoking, alcohol drinking, physical activity, sys-
tolic blood pressure, total cholesterol, and triglycerides.
Therefore, an increase of 1.0 mg/dL in HDL cholesterol
was associated with a decrease of 10 mL in both FVC and
FEV1. However, the same association was not significant in
female adolescents. To evaluate whether socio-economic
status has any effect on the association between HDL chol-
esterol and pulmonary function, we performed further
Table 1 Participants’ characteristics
Variable Males (n = 318) Females (n = 326) p-value
Mean ± standard deviation
Age, year 15.8 ± 0.3 15.8 ± 0.3 0.997
Height, cm 171.2 ± 5.4 159.9 ± 5.0 <.001
Weight, kg 64.5 ± 10.3 54.1 ± 7.3 <.001
Body mass index, kg/m2 22.0 ± 3.1 21.1 ± 2.6 <.001
Waist circumference, cm 74.0 ± 8.1 69.2 ± 6.7 <.001
Systolic BP, mmHg 112.5 ± 11.6 102.8 ± 9.9 <.001
Diastolic BP, mmHg 59.3 ± 6.9 59.4 ± 6.7 0.954
Total cholesterol, mg/dL 148.4 ± 26.6 160.9 ± 25.8 <.001
HDL cholesterol, mg/dL 41.5 ± 8.6 47.5 ± 9.4 <.001
LDL cholesterol, mg/dL 90.3 ± 23.2 97.6 ± 22.6 <.001
Triglycerides, mg/dL 83.5 ± 31.3 78.9 ± 26.9 0.059
FVC, L 4.51 ± 0.62 3.23 ± 0.39 <.001
FEV1, L 3.98 ± 0.53 2.84 ± 0.40 <.001
Percent predicted FEV1 109.4 ± 11.5 90.6 ± 12.1 <.001
Percent predicted FVC 114.2 ± 12.8 98.3 ± 10.1 <.001
Number (%)
Smoking (≥100 cigarettes) 15 (4.7) 3 (0.9) 0.004
Drinking (≥1 time/month) 34 (10.7) 16 (4.9) 0.006
Regular exercise (≥1 time/week) 281 (88.4) 259 (79.5) 0.002
Monthly household income
< 3,000,000 won 61 (19.2) 51 (15.6) 0.622
3,000,000 to 5,000,000 won 101 (31.8) 112 (34.4)
> 5,000,000 won 80 (25.2) 79 (24.2)
Do not wish to answer 76 (23.9) 84 (25.8)
Data presented as mean ± standard deviation or as n (%)
Abbreviations: HDL high density lipoprotein, LDL low density lipoprotein, FVC forced vital capacity, FEV1 forced expiratory volume in one second
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analysis with additional adjustment for monthly household
income level. However, the association did not change.
Discussion
This study showed an association between HDL choles-
terol and pulmonary function in males only. The find-
ings remained consistent after adjusting for age, height,
weight, physical activity, systolic blood pressure, and
total cholesterol and triglyceride levels.
A recent study showed that elevated apolipoprotein M
gene expression and higher levels of HDL cholesterol are
associated with a lower FEV1/FVC ratio [12], corroborating
our findings. The present study was not designed to deter-
mine the mechanisms leading to apolipoprotein M eleva-
tion, but it is known that the serum levels of apolipoprotein
M and HDL cholesterol are positively correlated [17, 18]. A
previous study showed that levels of HDL cholesterol were
elevated in patients with chronic obstructive pulmonary
disease compared with a reference participant group with-
out disease [19]. In this regard, our results add to earlier
findings that HDL cholesterol is also associated with
impaired pulmonary function, independent of confounders,
Table 2 Correlations between lung function and relevant factors, stratified by sex
Variable FVC FEV1 Percent predicted FVC Percent predicted FEV1 FEV1/FVC, %
r p r p r p r p r p
Men (n = 318)
Age 0.135 0.016 0.149 0.008 0.193 0.001 0.208 <.001 0.027 0.637
Body mass index 0.338 <.001 0.203 <.001 0.455 <.001 0.293 <.001 −0.274 <.001
Systolic blood pressure 0.192 0.001 0.128 0.023 0.219 <.001 0.148 0.008 −0.116 0.039
Diastolic blood pressure 0.053 0.349 0.015 0.784 −0.013 0.812 −0.063 0.261 −0.058 0.305
Total cholesterol −0.049 0.388 −0.044 0.431 −0.084 0.135 −0.070 0.216 −0.021 0.708
HDL cholesterol −0.158 0.005 −0.137 0.015 −0.172 0.002 −0.165 0.003 0.037 0.514
Triglycerides 0.006 0.916 0.013 0.823 −0.005 0.927 0.003 0.955 0.003 0.951
Women (n = 326)
Age 0.020 0.719 0.028 0.617 0.076 0.174 0.096 0.082 0.028 0.619
Body mass index 0.220 <.001 0.197 <.001 0.358 <.001 0.301 <.001 −0.011 0.840
Systolic blood pressure 0.125 0.024 0.111 0.045 0.076 0.170 0.069 0.213 0.029 0.596
Diastolic blood pressure −0.039 0.484 −0.046 0.411 −0.063 0.259 −0.055 0.325 −0.008 0.880
Total cholesterol −0.068 0.221 −0.039 0.482 −0.018 0.748 0.003 0.961 0.055 0.322
HDL cholesterol −0.075 0.180 −0.050 0.375 −0.112 0.044 −0.087 0.121 0.000 0.994
Triglycerides 0.121 0.030 0.125 0.025 −0.009 0.877 0.030 0.594 0.077 0.167
Abbreviations: HDL high density lipoprotein, FVC forced vital capacity, FEV1 forced expiratory volume in one second
Fig. 1 Association between HDL cholesterol level and percent predicted FVC
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in healthy adolescents. However, in contrast to the current
study, previous studies have suggested that serum levels of
HDL cholesterol are positively correlated with pulmonary
function in participants with and without asthma [20, 21].
In previous studies of the relationship between metabolic
abnormalities and pulmonary function, elevated serum tri-
glyceride and low HDL cholesterol were independent pre-
dictors of impaired pulmonary function [22, 23]. A cross-
sectional study of adolescents found that those with low
HDL cholesterol levels had lower FEV1/FVC ratios [24].
After adjusting for adiposity, HDL cholesterol remained a
predictor of FEV1/FVC ratio.
Although the underlying mechanism is not yet under-
stood, the composition of pulmonary surfactant might be
a possible link between increased HDL cholesterol level
and decreased pulmonary function. First, increasing HDL
cholesterol could change the surface properties of pul-
monary surfactant, a complex mixture of lipids and pro-
teins. The mature lung contains approximately 300
million alveoli that each maintain their own function des-
pite their very small radii [25]. This is because there is an
air-liquid interface at which surface tension exists. Here,
pulmonary surfactant reduces the surface tension in order
to avoid collapse of alveolar architecture at the end of
Fig. 2 Association between HDL cholesterol level and percent predicted FEV1
Table 3 Multiple linear regression between HDL cholesterol and pulmonary function
Variable FVC, L FEV1, L Percent predicted FVC Percent predicted FEV1
β p β p β p β p
Males (n = 318)
Model 1 −0.011 0.003 −0.009 0.005 −0.285 0.001 −0.247 0.001
Model 2 −0.008 0.039 −0.008 0.015 −0.172 0.024 −0.195 0.007
Model 3 −0.008 0.039 −0.008 0.014 −0.185 0.017 −0.209 0.004
Model 4 −0.010 0.028 −0.010 0.014 −0.192 0.036 −0.210 0.017
Model 5 −0.010 0.013 −0.010 0.013 −0.192 0.036 −0.209 0.017
Females (n = 326)
Model 1 −0.003 0.312 −0.002 0.429 −0.088 0.141 −0.071 0.328
Model 2 −0.001 0.604 −0.001 0.787 −0.034 0.556 −0.011 0.873
Model 3 −0.002 0.535 −0.001 0.693 −0.037 0.519 −0.017 0.809
Model 4 0.002 0.497 0.002 0.464 −0.036 0.597 −0.015 0.858
Model 5 0.001 0.636 0.002 0.445 −0.046 0.499 −0.005 0.952
Model 1: unadjusted
Model 2: adjusted for age, height, and weight
Model 3: adjusted for age, height, weight, alcohol drinking, smoking, and exercise
Model 4: adjusted for age, height, weight, alcohol drinking, smoking, exercise, systolic blood pressure, total cholesterol, and triglycerides
Model 5: adjusted for age, height, weight, alcohol drinking, smoking, exercise, systolic blood pressure, total cholesterol, and triglycerides, and monthly
household income
Abbreviations: FVC forced vital capacity, FEV1 forced expiratory volume in one second
Park et al. BMC Pulmonary Medicine  (2017) 17:190 Page 5 of 7
expiration and to assist the work of breathing [26, 27]. A
recent study found that, of all serum components indi-
vidually tested, HDL cholesterol modified the surface
properties of surfactant [28]. Another possibility is that
HDL cholesterol inhibits tumor necrosis factor-alpha (TNF-
α) stimulated sphingosine kinase activity in endothelial cells,
resulting not only in decreased sphingosine 1-phosphate
production but also increased ceramide [12, 29]. Ceramide,
the central molecule in the sphingolipid pathway, has been
shown to induce apoptosis in experimental mouse models
of emphysema [30]. In addition, a previous study has shown
that increased levels of ceramide affect surfactant produc-
tion [31]. Decreased pulmonary function could be due to
HDL cholesterol-modified surface tension, as well as
increased rigidity in the polar region of the surfactant.
In our study, the inverse association between HDL and
pulmonary function was observed only in male adoles-
cents. This sex-specific difference may be due to differ-
ence in absolute levels of HDL cholesterol. Women have
higher HDL cholesterol levels compared with men of the
same age. HDL cholesterol levels peak at 10–14 years of
age in men and at 25–59 years of age in women [32]. A
cohort study of 259 premenopausal women showed that
both hormones and lipoprotein cholesterol levels varied
across the menstrual cycle. Total and low-density lipopro-
tein cholesterol were highest during the follicular phase
and declined during the luteal phase, whereas HDL chol-
esterol was highest at the time of ovulation [33]. It has
been also reported that menopause is associated with
lower FVC and FEV1 [34, 35]. When lipoprotein choles-
terol levels vary across the menstrual cycle, it is difficult to
observe the association between HDL and pulmonary
function without considering the cyclic variations in lipo-
protein levels in female adolescents. Consequently, sex
hormones may act as a confounder influencing the
observed sex differences in the association between HDL
cholesterol and pulmonary function.
This study has some limitations. First, spirometry
results depend not only on the true lung function of the
participants but also on the quality of their test perform-
ance. Our analysis was limited to participants who had a
minimum of three technically satisfactory pulmonary
function measurements. Since interpretable spirometry
data were collected irrespective of HDL cholesterol level,
this should not have created significant bias. However,
female adolescents were more likely to perform poorly
on pulmonary function testing, which could underesti-
mate their own lung function and attenuate the study
results towards the null. Second, the cross-sectional
design has some disadvantages compared with a cohort
study, which is generally preferred to assess causal asso-
ciation. In this study, however, the underlying direction
of causality is relatively distinct with regard to the effect
of HDL cholesterol on pulmonary function. Third, most
of the study participants were in the midst of puberty,
thus hormonal status may influence the indices of
anthropometry, as well as HDL cholesterol. Female ado-
lescents enter puberty earlier and have a greater fat
mass; these could be potential confounding factors when
comparing the sexes. Finally, this study was conducted
at a single high school and included one ethnic group;
thus, the study findings cannot be generalized to other
adolescent populations. However, the participants in this
study were living in the same rural area, so there was no
difference in environmental exposures that could affect
lung function.
Conclusions
This study suggests that high HDL cholesterol may be
associated with decreased pulmonary function among
healthy male adolescents. The observed sex differences in
the association between HDL cholesterol and pulmonary
function warrant further investigation.
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